Neuland laboratories has announced its Q4FY26 earnings call scheduled for May 12, 2026, following the release of quarterly and annual results for the period ended March 31, 2026. The pharmaceutical company has formally notified stock exchanges about the upcoming earnings discussion as per regulatory requirements.

Earnings Call Details

The company has provided specific timing and scheduling information for the upcoming earnings call:

Regulatory Compliance

Neuland Laboratories has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015. The company secretary Sarada Bhamidipati signed the formal intimation dated April 29, 2026, which was submitted to both BSE Limited and The National Stock Exchange of India Ltd.

Company Background

Neuland Labs operates as a pharmaceutical manufacturer with significant global presence. The company has established manufacturing capabilities across multiple markets:

• Global Reach: Operations in close to 80 countries
• Product Portfolio: More than 300 processes and 100 APIs developed
• Regulatory Filings: Around 995+ regulatory filings including 75 active US DMFs
• Experience: Over 4 decades in API manufacturing

Quality Certifications

The company maintains extensive regulatory certifications across major global markets including U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, and various ISO certifications including ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

Contact Information

Investors and stakeholders can access additional information through the company's investor relations team at ir@neulandlabs.com or visit the official website at www.NeulandLabs.com for comprehensive details about the upcoming results and earnings call.

Davuluri Ownership Trust has submitted its annual compliance certificate to stock exchanges for the financial year ended March 31, 2026, confirming adherence to regulatory requirements under a SEBI exemption order. The trust, led by Trustee Dr. Davuluri Rama Mohan Rao, filed the certificate with both BSE Limited and The National Stock Exchange of India Limited on April 9, 2026.

Regulatory Compliance Framework

The compliance certificate was issued pursuant to SEBI Exemption Order No. WTM/ASB/CFD/17/2024-25 dated January 3, 2025, read with regulation 11 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The submission relates to the trust's shareholding in Neuland Laboratories Limited, which trades under scrip codes 524558 on BSE and NEULANDLAB on NSE.

Independent Audit Verification

The compliance certificate was issued by B Srinivasa Rao & Co., Chartered Accountants, who served as independent auditors to verify the trust's compliance status. CA Ranga Rai Chowdary M, Partner with membership number 243733, signed the certificate on April 7, 2026, from the firm's Hyderabad office.

The audit scope encompassed verification of compliance with:

• Conditions specified in the SEBI exemption order
• Disclosure and governance requirements under SEBI SAST Regulations
• Trust deed provisions and related documentation
• Necessary disclosures to stock exchanges and SEBI

Auditor's Assessment and Opinion

The independent auditors conducted their examination in accordance with guidance notes issued by the Institute of Chartered Accountants of India for special purpose reports. They confirmed compliance with ethical requirements and quality control standards applicable to audit engagements.

Based on their examination of relevant records and information provided, the auditors certified that Davuluri Ownership Trust complied with all conditions stipulated in the SEBI exemption order and applicable SAST regulation provisions for the year ended March 31, 2026.

Regulatory Framework and Limitations

The trust's management holds responsibility for ensuring compliance with applicable SEBI regulations and maintaining proper accounting and supporting records. This includes designing and implementing internal controls relevant to regulatory compliance and providing necessary information to SEBI as required.

The auditors noted that their certificate was issued solely for submission to SEBI and stock exchanges under the aforementioned order and should not be used for any other purpose. The compliance certificate was also copied to SEBI's Mumbai office and the Company Secretary of Neuland Laboratories Limited in Hyderabad, ensuring all relevant regulatory bodies and the target company were informed of the trust's continued compliance status.